FDA grants tentative approval for Liquidia's YUTREPIA but final approval delayed to May 2025 due to exclusivity

Liquidia Corp

FDA granted tentative approval of YUTREPIA (treprostinil) inhalation powder for PAH and PH-ILD on Aug 19, 2024.
Final approval delayed until after expiration of Tyvaso DPI's three-year new dosage form exclusivity on May 23, 2025.
Liquidia plans to challenge FDA's broad grant of regulatory exclusivity to United Therapeutics for Tyvaso DPI.
Tentative approval confirms YUTREPIA meets FDA standards for quality, safety, and efficacy but cannot be marketed yet.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.